arrow
M

Mark G. Ward

university hospital of saint-etienne, saint-etienne, france
H指数:17
被引数:1,119

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis

炎症性肠病患者通过1年维持治疗使用vedolizumab或皮下注射infliximab因疗效不足而停药的比例:一项系统文献综述和荟萃分析

2025-10-080
OA
Association of gut microbiota changes and disease activity in patients with Crohn's disease and ulcerative colitis: baseline data from the Australian IBD Microbiome study
2025-01-220
PRE
Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease-Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics

炎症性肠病中皮下注射英夫利昔单抗的治疗药物监测-了解皮下生物制剂新时代的药代动力学和暴露反应关系

2022-10-1922
OAAI
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure
2020-09-2741
OAAI